<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T20:04:37Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:5412892" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:5412892</identifier><datestamp>2017-05-15</datestamp><setSpec>blackwellopen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Hum Mutat</journal-id>
      <journal-id journal-id-type="iso-abbrev">Hum. Mutat</journal-id>
      <journal-id journal-id-type="doi">10.1002/(ISSN)1098-1004</journal-id>
      <journal-id journal-id-type="publisher-id">HUMU</journal-id>
      <journal-title-group>
        <journal-title>Human Mutation</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1059-7794</issn>
      <issn pub-type="epub">1098-1004</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC5412892</article-id>
      <article-id pub-id-type="pmcid">PMC5412892</article-id>
      <article-id pub-id-type="pmc-uid">5412892</article-id>
      <article-id pub-id-type="pmid">28101991</article-id>
      <article-id pub-id-type="doi">10.1002/humu.23181</article-id>
      <article-id pub-id-type="publisher-id">HUMU23181</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Research Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity</article-title>
        <alt-title alt-title-type="right-running-head">HUMAN MUTATION</alt-title>
      </title-group>
      <contrib-group>
        <contrib id="humu23181-cr-0001" contrib-type="author">
          <name>
            <surname>Mendes</surname>
            <given-names>Marisa I</given-names>
          </name>
          <xref ref-type="aff" rid="humu23181-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="humu23181-cr-0002" contrib-type="author">
          <name>
            <surname>Smith</surname>
            <given-names>DesirÃ©e EC</given-names>
          </name>
          <xref ref-type="aff" rid="humu23181-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="humu23181-cr-0003" contrib-type="author">
          <name>
            <surname>Pop</surname>
            <given-names>Ana</given-names>
          </name>
          <xref ref-type="aff" rid="humu23181-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="humu23181-cr-0004" contrib-type="author">
          <name>
            <surname>Lennertz</surname>
            <given-names>Pascal</given-names>
          </name>
          <xref ref-type="aff" rid="humu23181-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="humu23181-cr-0005" contrib-type="author">
          <name>
            <surname>Fernandez Ojeda</surname>
            <given-names>Matilde R</given-names>
          </name>
          <xref ref-type="aff" rid="humu23181-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="humu23181-cr-0006" contrib-type="author">
          <name>
            <surname>Kanhai</surname>
            <given-names>Warsha A</given-names>
          </name>
          <xref ref-type="aff" rid="humu23181-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="humu23181-cr-0007" contrib-type="author">
          <name>
            <surname>van Dooren</surname>
            <given-names>Silvy JM</given-names>
          </name>
          <xref ref-type="aff" rid="humu23181-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="humu23181-cr-0008" contrib-type="author">
          <name>
            <surname>Anikster</surname>
            <given-names>Yair</given-names>
          </name>
          <xref ref-type="aff" rid="humu23181-aff-0002">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="humu23181-cr-0009" contrib-type="author">
          <name>
            <surname>BariÄ</surname>
            <given-names>Ivo</given-names>
          </name>
          <xref ref-type="aff" rid="humu23181-aff-0003">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="humu23181-cr-0010" contrib-type="author">
          <name>
            <surname>Boelen</surname>
            <given-names>Caroline</given-names>
          </name>
          <xref ref-type="aff" rid="humu23181-aff-0004">
<sup>4</sup>
</xref>
        </contrib>
        <contrib id="humu23181-cr-0011" contrib-type="author">
          <name>
            <surname>Campistol</surname>
            <given-names>Jaime</given-names>
          </name>
          <xref ref-type="aff" rid="humu23181-aff-0005">
<sup>5</sup>
</xref>
        </contrib>
        <contrib id="humu23181-cr-0012" contrib-type="author">
          <name>
            <surname>de Boer</surname>
            <given-names>Lonneke</given-names>
          </name>
          <xref ref-type="aff" rid="humu23181-aff-0006">
<sup>6</sup>
</xref>
        </contrib>
        <contrib id="humu23181-cr-0013" contrib-type="author">
          <name>
            <surname>Kariminejad</surname>
            <given-names>Ariana</given-names>
          </name>
          <xref ref-type="aff" rid="humu23181-aff-0007">
<sup>7</sup>
</xref>
        </contrib>
        <contrib id="humu23181-cr-0014" contrib-type="author">
          <name>
            <surname>Kayserili</surname>
            <given-names>Hulya</given-names>
          </name>
          <xref ref-type="aff" rid="humu23181-aff-0008">
<sup>8</sup>
</xref>
        </contrib>
        <contrib id="humu23181-cr-0015" contrib-type="author">
          <name>
            <surname>Roubertie</surname>
            <given-names>Agathe</given-names>
          </name>
          <xref ref-type="aff" rid="humu23181-aff-0009">
<sup>9</sup>
</xref>
          <xref ref-type="aff" rid="humu23181-aff-0010">
<sup>10</sup>
</xref>
        </contrib>
        <contrib id="humu23181-cr-0016" contrib-type="author">
          <name>
            <surname>Verbruggen</surname>
            <given-names>Krijn T</given-names>
          </name>
          <xref ref-type="aff" rid="humu23181-aff-0011">
<sup>11</sup>
</xref>
        </contrib>
        <contrib id="humu23181-cr-0017" contrib-type="author">
          <name>
            <surname>VianeyâSaban</surname>
            <given-names>Christine</given-names>
          </name>
          <xref ref-type="aff" rid="humu23181-aff-0012">
<sup>12</sup>
</xref>
        </contrib>
        <contrib id="humu23181-cr-0018" contrib-type="author">
          <name>
            <surname>Williams</surname>
            <given-names>Monique</given-names>
          </name>
          <xref ref-type="aff" rid="humu23181-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="humu23181-cr-0019" contrib-type="author" corresp="yes">
          <name>
            <surname>Salomons</surname>
            <given-names>Gajja S</given-names>
          </name>
          <address>
            <email>g.salomons@vumc.nl</email>
          </address>
          <xref ref-type="aff" rid="humu23181-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="humu23181-aff-0001">
        <label>
          <sup>1</sup>
        </label>
        <named-content content-type="organisation-division">Department of Clinical Chemistry</named-content>
        <named-content content-type="organisation-division">Metabolic Unit</named-content>
        <named-content content-type="organisation-division">VU University Medical Center</named-content>
        <institution>Amsterdam Neuroscience</institution>
        <named-content content-type="country-part">Amsterdam</named-content>
        <country country="NL">The Netherlands</country>
      </aff>
      <aff id="humu23181-aff-0002">
        <label>
          <sup>2</sup>
        </label>
        <named-content content-type="organisation-division">Edmond and Lily Safra Children's Hospital</named-content>
        <named-content content-type="organisation-division">Sheba Medical Center and Sackler School of Medicine</named-content>
        <institution>Tel Aviv University</institution>
        <country country="IL">Israel</country>
      </aff>
      <aff id="humu23181-aff-0003">
        <label>
          <sup>3</sup>
        </label>
        <named-content content-type="organisation-division">Department of Pediatrics</named-content>
        <institution>University Hospital Center Zagreb &amp; University of Zagreb, School of Medicine</institution>
        <named-content content-type="country-part">Zagreb</named-content>
        <country country="HR">Croatia</country>
      </aff>
      <aff id="humu23181-aff-0004">
        <label>
          <sup>4</sup>
        </label>
        <named-content content-type="organisation-division">Department of Pediatrics</named-content>
        <institution>Admiraal De Ruyter Ziekenhuis</institution>
        <named-content content-type="city">Goes</named-content>
        <named-content content-type="country-part">Zeeland</named-content>
        <country country="NL">The Netherlands</country>
      </aff>
      <aff id="humu23181-aff-0005">
        <label>
          <sup>5</sup>
        </label>
        <named-content content-type="organisation-division">Neurology Department</named-content>
        <named-content content-type="organisation-division">CIBERER ISCIII</named-content>
        <named-content content-type="organisation-division">Hospital Sant Joan de Deu</named-content>
        <institution>University of Barcelona</institution>
        <named-content content-type="country-part">Barcelona</named-content>
        <country country="ES">Spain</country>
      </aff>
      <aff id="humu23181-aff-0006">
        <label>
          <sup>6</sup>
        </label>
        <named-content content-type="organisation-division">Department of pediatrics, metabolic diseases</named-content>
        <institution>Radboud University Medical Center</institution>
        <named-content content-type="city">Nijmegen</named-content>
        <country country="NL">The Netherlands</country>
      </aff>
      <aff id="humu23181-aff-0007">
        <label>
          <sup>7</sup>
        </label>
        <institution>KariminejadâNajmabadi Pathology &amp; Genetics Center</institution>
        <named-content content-type="country-part">Tehran</named-content>
        <country country="IR">Iran</country>
      </aff>
      <aff id="humu23181-aff-0008">
        <label>
          <sup>8</sup>
        </label>
        <named-content content-type="organisation-division">Medical Genetics Department</named-content>
        <institution>KoÃ§ University School of Medicine (KUSOM)</institution>
        <named-content content-type="country-part">Istanbul</named-content>
        <country country="TR">Turkey</country>
      </aff>
      <aff id="humu23181-aff-0009">
        <label>
          <sup>9</sup>
        </label>
        <named-content content-type="organisation-division">DÃ©partement de NeuropÃ©diatrie</named-content>
        <institution>Hopital Gui de Chauliac</institution>
        <named-content content-type="city">Montpellier</named-content>
        <named-content content-type="country-part">LanguedocâRoussillon</named-content>
        <country country="FR">France</country>
      </aff>
      <aff id="humu23181-aff-0010">
        <label>
          <sup>10</sup>
        </label>
        <named-content content-type="organisation-division">INSERM U1051</named-content>
        <institution>Institut des Neurosciences de Montpellier</institution>
        <named-content content-type="city">Montpellier</named-content>
        <country country="FR">France</country>
      </aff>
      <aff id="humu23181-aff-0011">
        <label>
          <sup>11</sup>
        </label>
        <named-content content-type="organisation-division">Beatrix Children's Hospital, University Medical Center Groningen</named-content>
        <institution>University of Groningen</institution>
        <named-content content-type="country-part">Groningen</named-content>
        <country country="NL">The Netherlands</country>
      </aff>
      <aff id="humu23181-aff-0012">
        <label>
          <sup>12</sup>
        </label>
        <named-content content-type="organisation-division">Centre de Biologie et de Pathologie Est CHU de Lyon</named-content>
        <institution>Service Maladies HÃ©rÃ©ditaires du MÃ©tabolisme et DÃ©pistage NÃ©onatal</institution>
        <named-content content-type="city">Lyon</named-content>
        <country country="FR">France</country>
      </aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label>Correspondence to: Gajja S. Salomons, VU University Medical Center, Metabolic Laboratory, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands. Eâmail: <email>g.salomons@vumc.nl</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>14</day>
        <month>2</month>
        <year>2017</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>5</month>
        <year>2017</year>
      </pub-date>
      <volume>38</volume>
      <issue>5</issue>
      <issue-id pub-id-type="doi">10.1002/humu.2017.38.issue-5</issue-id>
      <fpage>524</fpage>
      <lpage>531</lpage>
      <history>
        <date date-type="received">
          <day>22</day>
          <month>11</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>1</month>
          <year>2017</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2017 Wiley Periodicals, Inc. <copyright-statement>-->
        <copyright-statement content-type="article-copyright">Â© 2017 The Authors. <sup>**</sup><italic>Human Mutation</italic> published by Wiley Periodicals, Inc.</copyright-statement>
        <license license-type="creativeCommonsBy">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:HUMU-38-524.pdf"/>
      <abstract>
        <title>ABSTRACT</title>
        <p>We describe 14 patients with 12 novel missense mutations in <italic>ASPA</italic>, the gene causing Canavan disease (CD). We developed a method to study the effect of these 12 variants on the function of aspartoacylaseâthe hydrolysis of Nâacetylâ<sc>l</sc>âaspartic acid (NAA) to aspartate and acetate. The wildâtype <italic>ASPA</italic> open reading frame (ORF) and the ORFs containing each of the variants were transfected into HEK293 cells. Enzyme activity was determined by incubating cell lysates with NAA and measuring the released aspartic acid by LCâMS/MS. Clinical data were obtained for 11 patients by means of questionnaires. Four patients presented with a nonâtypical clinical picture or with the milder form of CD, whereas seven presented with severe CD. The mutations found in the mild patients corresponded to the variants with the highest residual enzyme activities, suggesting that this assay can help evaluate unknown variants found in patients with atypical presentation. We have detected a correlation between clinical presentation, enzyme activity, and genotype for CD.</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated">
        <kwd id="humu23181-kwd-0001">Canavan disease</kwd>
        <kwd id="humu23181-kwd-0002">
          <italic>ASPA</italic>
        </kwd>
        <kwd id="humu23181-kwd-0003">ASPA activity</kwd>
        <kwd id="humu23181-kwd-0004">missense variants</kwd>
        <kwd id="humu23181-kwd-0005">clinical phenotype</kwd>
        <kwd id="humu23181-kwd-0006">functional assay</kwd>
      </kwd-group>
      <counts>
        <fig-count count="4"/>
        <table-count count="1"/>
        <page-count count="8"/>
        <word-count count="6384"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>component-id</meta-name>
          <meta-value>humu23181</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>May 2017</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.9 mode:remove_FC converted:02.05.2017</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <fn-group>
        <fn id="humu23181-note-0001">
          <p>Communicated by Jan P. Kraus</p>
        </fn>
      </fn-group>
    </notes>
  </front>
  <body>
    <sec id="humu23181-sec-0010">
      <title>Introduction</title>
      <p>Canavan disease (CD, MIM# 271900) is an autosomal recessive neurodegenerative disease characterized by spongy degeneration of the white matter of the brain [Canavan, <xref rid="humu23181-bib-0004" ref-type="ref">1931</xref>; van Bogaert and Bertrand, <xref rid="humu23181-bib-0034" ref-type="ref">1949</xref>]. It is caused by deficiency of the enzyme aspartoacylase (ASPA) [Matalon etÂ al., <xref rid="humu23181-bib-0017" ref-type="ref">1988</xref>]. Symptoms usually appear after normal development during the first months of life and progress rapidly. They include macrocephaly, hypotonia, loss of muscle control, feeding difficulties, developmental delay (including motor and verbal skills), and visual impairment. Some patients develop seizures [Traeger and Rapin, <xref rid="humu23181-bib-0032" ref-type="ref">1998</xref>; Surendran etÂ al., <xref rid="humu23181-bib-0029" ref-type="ref">2003b</xref>]. At this moment, there is no proven therapy for CD. Use of gene therapy is being investigated and clinical trials are being performed, some of which show limited success in slowing the progression of the disease [Leone etÂ al., <xref rid="humu23181-bib-0013" ref-type="ref">2012</xref>]. ASPA is the only known enzyme able to hydrolyze Nâacetylâ<sc>l</sc>âaspartic acid (NAA) into aspartate (Asp) and acetate. ASPA deficiency results in accumulation of NAA in body fluids. Elevation of NAA levels in urine is the biochemical hallmark of CD. Molecular analysis of <italic>ASPA</italic> gene (MIM# 608034, NG_008399.1) is the confirmative test. This gene is located on chromosome 17 (17p13.2). It is composed of six exons and comprises about 30Â kb. More than 100 mutations in <italic>ASPA</italic> have been submitted to the Leiden Open Variation Database (LOVD), including deletions, missense mutations, and nonsense mutations (<ext-link ext-link-type="uri" xlink:href="http://www.lovd.nl/ASPA">http://www.lovd.nl/ASPA</ext-link>). CD carrier frequency among Ashkenazi Jewish populations is relatively high: one in 30 to one in 60, corresponding to an incidence of one in 5,000 to one in 6,700 [Kronn etÂ al., <xref rid="humu23181-bib-0010" ref-type="ref">1995</xref>; Matalon etÂ al., <xref rid="humu23181-bib-0016" ref-type="ref">1995</xref>; Feigenbaum etÂ al., <xref rid="humu23181-bib-0006" ref-type="ref">2004</xref>]. Only two mutations are responsible for about 98% of CD alleles in this population [Matalon, <xref rid="humu23181-bib-0014" ref-type="ref">1997</xref>]. The mutation c.854A&gt;C, p.Glu285Ala is responsible for about 84% of CD alleles, whereas the mutation c.693C&gt;A, p.Y231X is found in about 14% of CD alleles. Both mutations are associated with a severe phenotype. The overall incidence is much lower (one in 200,000 to one to 400,000). Here, the most common mutation responsible for about 40%â48% of the CD alleles is c.914C&gt;A, p.Ala305Glu. This mutation has been associated with both severe and mild phenotypes [Shaag etÂ al., <xref rid="humu23181-bib-0024" ref-type="ref">1995</xref>].</p>
      <p>ASPA (EC3.5.1.15) is a dimeric metalloenzyme composed by 37Â kDa monomers (313 amino acid residues). It is mainly present in brain white matter (mainly oligodendrocytes) and kidney [Baslow etÂ al., <xref rid="humu23181-bib-0001" ref-type="ref">1999</xref>; Sommer and Sass, <xref rid="humu23181-bib-0026" ref-type="ref">2012</xref>]. The crystal structure of ASPA has been resolved (Bitto etÂ al., <xref rid="humu23181-bib-0003" ref-type="ref">2007</xref>; Le Coq etÂ al., <xref rid="humu23181-bib-0012" ref-type="ref">2008</xref>). ASPA binds one atom of Zn per monomer [Le Coq etÂ al., <xref rid="humu23181-bib-0011" ref-type="ref">2006</xref>] and this metal is necessary for the enzyme reaction. The amino acid residues involved in Zn binding are His21, Glu24, and His116. The catalytic site is composed of residues Arg63, Asn70, Arg71, Tyr164, Arg168, Glu178, and Tyr288. Residues Arg168 and Tyr288 stabilize the binding of NAA to ASPA. It was shown that due to rare codon usage, eukaryotic expression systems need to be used to properly study enzyme variants [Wang and Viola, <xref rid="humu23181-bib-0036" ref-type="ref">2014</xref>]. The vast majority of <italic>ASPA</italic> mutations that have been overexpressed in COS or human embryonic kidney (HEK)293 cells present very low enzyme activity (lower than 5% of wildâtype (WT)) [Janson etÂ al., <xref rid="humu23181-bib-0008" ref-type="ref">2006</xref>; Sommer and Sass, <xref rid="humu23181-bib-0026" ref-type="ref">2012</xref>; Surendran etÂ al., <xref rid="humu23181-bib-0028" ref-type="ref">2003a</xref>].</p>
      <p>In this article, we report a method for the characterization of missense variants in <italic>ASPA</italic> gene transiently transfected into HEK293 cells. A total of 14 patients (corresponding to 12 missense variants) were included in our study.</p>
    </sec>
    <sec id="humu23181-sec-0020">
      <title>Material and Methods</title>
      <sec id="humu23181-sec-0030">
        <title>Patients, Sample Collection, Mutational Analysis, and Inclusion Criteria</title>
        <p>From 1.1.2002 to 31.12.2015 genomic DNA was isolated from blood of patients suspected of CD on basis of clinical and biochemical findings, such as macrocephaly, hypotonia, developmental delay, and increased urinary excretion of NAA. To analyze the coding region of the <italic>ASPA</italic> gene, the six exons and intron boundaries were amplified by PCR. Sequence analysis was performed in both directions with ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction Kits, in an ABI PRISM 3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA). Sequences were compared with the reference sequence from the GenBank (NG_008399.1) using Mutation Surveyor (Softgenetics, State College, PA). Nucleotide numbering of variants reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence (NM_000049.2). Fourteen patients, harboring missense mutations not described in literature, were selected for this study. Physicians following these patients were invited to fill in a questionnaire covering clinical signs, clinical course, motor and cognitive development, NAA levels, and radiographic investigations. Eleven questionnaires were received. Patients were numbered 1â11 and divided into two groups based on their ability to achieve (minimal) speech and their ability to walk.</p>
      </sec>
      <sec id="humu23181-sec-0040">
        <title>Construction of the ASPA Expression Vector and SiteâDirected Mutagenesis to Introduce Variants</title>
        <p>The human <italic>ASPA</italic> gene (NM_000049.2) encoding the enzyme ASPA was amplified by PCR using the primers ASPA_Clon_F, containing a restriction site for the enzyme Asi SI, and ASPA_Clon_R, containing a restriction site of the enzyme Rsr II (Supp. Table S1). After purification, the amplified fragment and the pCMV6 vector (Origene, Rockville, MD) were digested with the enzymes Asi SI (New England Biolabs, Ipswich, MA) and Rsr II (New England Biolabs) and ligated, in frame with mGFP. The final construct was used as a template to introduce the following mutations: c.70G&gt;A (p.Glu24Lys), c.89T&gt;C (p.Leu30Pro), c.170C&gt;T (p.Ala57Val), c.188G&gt;C (p.Arg63Thr), c.206T&gt;G (p.Leu69Arg), c.302G&gt;T (p.Gly101Val), c.385G&gt;A (p.Glu129Lys), c.509T&gt;C (p.Ile170Thr), c.539G&gt;T (p.Gly180Val), c.610G&gt;C (p.Asp204His), c.743A&gt;G (p.Gln248Arg), c.854A&gt;C (p.Glu285Ala), c.857C&gt;A (p.Ala286Asp), and c.914C&gt;A (p.Ala305Glu) by siteâdirected mutagenesis using the primers listed in Supp. Table 1, as described previously [Betsalel etÂ al., <xref rid="humu23181-bib-0002" ref-type="ref">2012</xref>]. The authenticity of mutagenesis and cloning was verified by DNA sequencing.</p>
      </sec>
      <sec id="humu23181-sec-0050">
        <title>Overexpression of ASPA Alleles in HEK293 Cells</title>
        <p>HEK293 cells were cultured to 70% confluency and used for transient expression of the obtained constructs. For the transfections, 12Â Î¼g of plasmid DNA was incubated with 60Â Î¼l of Fugene (Promega, Madison, WI) at room temperature for 15Â min in serumâfree DMEM medium (Thermo Fisher Scientific, Waltham, MA). The complex was applied to the cells. Cells transfected either with WT pCMV6â<italic>ASPA</italic> (from here on related to as WT), the empty vector (mock transfected) as well as untransfected cells were included as controls. The most common variants found in patients from Ashkenazi Jewish background (c.854A&gt;C, p.Glu285Ala) and in nonâJewish populations (c.914C&gt;A, p.Ala305Glu) were also included as controls. Fluorescent microscopy was used to estimate transfection efficiency. Cells were harvested 48Â hr after transfection, flashâfrozen, and stored at â80Â°C until further use. Transfections were performed in triplicate.</p>
      </sec>
      <sec id="humu23181-sec-0060">
        <title>Functional Analysis of ASPA Variants by Novel Enzyme Assay</title>
        <p>A novel enzyme assay was developed in which the production of Asp from NAA was measured by LCâMS/MS. Cell pellets were suspended in 200Â Î¼l of 200Â mmol/l Tris buffer (pHÂ =Â 8.5) containing 0.5Â mmol/l phenylmethylsulfonyl fluoride. Cell membranes were disrupted by three freezeâthaw cycles. The supernatant was collected following 5Â min centrifugation at 13,000<italic>g</italic> (11,000Â rpm) at 4Â°C. Approximately 10Â Î¼g of protein (1Â Î¼g for WT) was incubated for 30Â min at 37Â°C in 200Â Î¼l of 200Â mmol/l Tris buffer (pHÂ =Â 8.5) containing 1.25Â mmol/l of NAA. The reaction was terminated by placing the samples on ice and adding 20 Î¼l 200Â mmol/l nonafluoropentanoic acid. After 25Â Î¼l of [D3]âaspartic acid was added as an internal standard, the lysates were pipetted on a molecular weight cutâoff filter (mw 10.000; Amicon; Millipore, Billerica, MA) and centrifuged for 10Â min at 20,000<italic>g</italic> (14,000Â rpm) at 4Â°C. <italic>K</italic>
<sub>m</sub> value for WT was found to be 0.2Â mmol/l, in agreement with previously published data [Le Coq J. etÂ al., <xref rid="humu23181-bib-0011" ref-type="ref">2006</xref>].</p>
        <p>The aspartic acid formed was measured by positive electrospray triple quadrupole tandem mass spectrometry (API 5000; Applied Biosystems) coupled to a Shimadzu Nexera HPLC (Kyoto, Japan). Five microliters of the incubation mixture was separated on a Symmetry Shield C18 analytical column (3.5Â Î¼m, 3.0Â ÃÂ 100Â mm<sup>2</sup>; Waters, Milford, MA) using a mobile phase containing 5Â mmol/l nonafluoropentanoic acid. The gradient was started at 0% acetonitrile for 5Â min. In 4Â min, the acetonitrile content of the mobile phase was increased from 0% to 50%. Mass transitions <italic>m</italic>/<italic>z</italic> 134.1Â âÂ 88.1 and 137.1Â âÂ 91.1 were used for unlabeled and [D3] labeled aspartic acid. Intraâassay variations were 11% for WT and 4% for a variant with low activity (<italic>n</italic>Â =Â 6). Protein content was measured using the Bicinchoninic acid method (SigmaâAldrich, St Louis, MI). Bovine serum albumin was used as the standard. All determinations were performed in triplicate. The amounts of aspartic acid measured in WT and variant ASPA enzymes were corrected for endogenous aspartic acid and endogenous ASPA activity by subtracting the amount of aspartic acid measured in mockâtransfected cells.</p>
      </sec>
      <sec id="humu23181-sec-0070">
        <title>Western Blot</title>
        <p>To confirm the presence of ASPA protein in the transfected cells, a Western blot was performed. Cell pellets were resuspended in urea lysis buffer (10Â mmol/l Tris HCl, 8Â mol/l urea, 100Â mmol/l NaCl, pH 8.0). After DNA shearing using a 29 gauge needle, protein concentration was determined as described above and 30Â Î¼g of total protein was separated in a 12% stainâfree SDS gel (BioâRad Laboratories, Hercules, CA). Proteins were transferred onto a polyvinylidenfluoride membrane (BioâRad) using a TransâBlot Turbo Transfer System (BioâRad). Immunodetection was performed using a primary antibody (rabbit) directed at the GFP tag (ab290; Abcam, Cambridge, UK) and a secondary antiârabbit antibody (PO448; Dako, Glostrup, Denmark). Immune complexes were detected by enhanced chemiluminescence (Lumilight Plus), according to the manufacturer's specifications (Roche, Indianapolis, IN). Images were acquired in a CCD (chargeâcoupled device) imager ChemiDoc XRS (BioâRad) using the Image Lab software (BioâRad).</p>
      </sec>
      <sec id="humu23181-sec-0080">
        <title>Structural Modeling</title>
        <p>The crystal structure of the WT human ASPA (PDB ID:2O4H) was used as a template to generate structures for the variants addressed in this study using the online structural predictor SDM (<ext-link ext-link-type="uri" xlink:href="http://mordred.bioc.cam.ac.uk/~sdm/sdm.php">http://mordred.bioc.cam.ac.uk/~sdm/sdm.php</ext-link>). Molecular graphics and analyses were performed with the UCSF Chimera package. Chimera is developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (supported by NIGMS P41âGM103311) [Pettersen etÂ al., <xref rid="humu23181-bib-0021" ref-type="ref">2004</xref>].</p>
      </sec>
    </sec>
    <sec id="humu23181-sec-0090">
      <title>Results</title>
      <sec id="humu23181-sec-0100">
        <title>Genotypic Characterization of Patients</title>
        <p>DNA sequencing was used to confirm diagnosis of CD in 84 patients in our laboratory. Twelve novel missense variants were detected in 14 patients, who were selected for this study: nine homozygous and five compound heterozygous patients. Figure <xref rid="humu23181-fig-0001" ref-type="fig">1</xref> depicts the structure of the ASPA monomer with the location of the 12 affected residues as well as the two most common variants. All mutations result in the replacement of amino acid residues that are very conserved across species. The identified mutations have been included in the Leiden LOVD (<ext-link ext-link-type="uri" xlink:href="http://www.lovd.nl/ASPA">http://www.lovd.nl/ASPA</ext-link>). A scheme of all mutations reported in <italic>ASPA</italic> gene is depicted in Figure <xref rid="humu23181-fig-0002" ref-type="fig">2</xref>.</p>
        <fig fig-type="Figure" xml:lang="en" id="humu23181-fig-0001" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Schematic and structural representation of the ASPA monomer with the location of the amino acid residues addressed in this study. The structural image was generated using the crystal structure of ASPA (PDB ID: 2O4H), obtained using the UCSF Chimera package. Chimera is developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (supported by NIGMS P41âGM103311).</p>
          </caption>
          <graphic id="nlm-graphic-3" xlink:href="HUMU-38-524-g001"/>
        </fig>
        <fig fig-type="Figure" xml:lang="en" id="humu23181-fig-0002" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Schematic representation of the <italic>ASPA</italic> gene and the distribution of all published mutations (as of September 2016). These mutations are part of the mutation database LOVD (<ext-link ext-link-type="uri" xlink:href="http://www.lovd.nl/ASPA">http://www.lovd.nl/ASPA</ext-link>). Variants located in exonic regions are in black, variants in intronic regions are in gray. Novel variants addressed in this study are represented in bold. Large deletions are depicted in the box.</p>
          </caption>
          <graphic id="nlm-graphic-5" xlink:href="HUMU-38-524-g002"/>
        </fig>
      </sec>
      <sec id="humu23181-sec-0110">
        <title>Clinical Features of Patients with New ASPA Mutations</title>
        <p>Eleven out of the 14 questionnaires sent out to the clinicians were returned. In one case, the clinician could not be contacted, the other two did not respond. Eleven out of 14 Canavan patients (six males) with new missense mutations were evaluated. First signs in this patient group appeared from birth (macrocephaly) up to an age of 6 years and 10 months. Followâup time was 6 months to 36 years (range 6â432 months, average 153, median 120 months). Four patients were lost to follow up (at 6, 24, 264, and 432 months); two of these had died. At the last follow up, six patients were still alive; of one this is unknown. First signs (provided for nine out of 11 patients) included developmental delay, hypotonia (head lag (<italic>n</italic>Â =Â 4), poor/no head control (<italic>n</italic>Â =Â 4)), decreased contact (<italic>n</italic>Â =Â 2), motor retardation (<italic>n</italic>Â =Â 1), movement abnormalities (<italic>n</italic>Â =Â 1), epilepsy (<italic>n</italic>Â =Â 1), intellectual disability (<italic>n</italic>Â =Â 1), loosing skills (<italic>n</italic>Â =Â 1), and behavioral problems (<italic>n</italic>Â =Â 1). Patients were categorized into two groups based on clinical presentation. The atypical/mild group was composed of patients 1â4. Patients 5â11 were part of the severely affected group.</p>
        <p>Clinical course in patients was unknown (<italic>n</italic>Â =Â 1), stable (<italic>n</italic>Â =Â 2), slowly progressive (<italic>n</italic>Â =Â 8), or rapidly progressive (<italic>n</italic>Â =Â 1). Rapid deterioration was described in four patients and was determined by the development of seizures in patients with either a slowly progressive (patients 2, 5, and 8) or rapidly progressive disease course (patient 9). Other signs during the course of disease were optic atrophy (one out of seven), developing spastic tetraparesis (three out of six), dysarthria (two out of 10) and nystagmus (one out of 10), amblyopia (one out of 10) and intermittent exotropia alternans (one out of 10).</p>
        <p>Head circumference was normal in patients 1, 2, 3, and 5. Macrocephaly was seen in all other patients with a severe phenotype; patient 10 was normocephalic at birth and developed macrocephaly with time. In nine out of 11 patients, height was within the normal range (â2SD to +2SD). Seven patients had a normal weight, whereas one was overweight (patient 3). No information on weight was available for two patients.</p>
        <p>Seizures were present in four out of 11 patients, starting from an age of 3 months to 8 years. Seizures were treated with either valproate or phenobarbital and topiramate (no information in one). Two patients (number 5 and 10) received uncommon drugs (lithium citrate or acetazolamide) without effect.</p>
        <p>Cognition was affected in all patients. Cognition was reported as severely deficient in seven patients. Five patients showed no speech development at all. In patients 1â4 (mild types), speech was less severely affected, with two of these patients receiving special or supportive education, the latter attending normal school (no information from patient 3). Of the severely affected group, patient 10 received special education with mild deficient cognition. In all other patients, no education was possible.</p>
        <p>All except four patients showed abnormal motor development. Patients 1, 2, and 3 were able to walk without support. Patient 4 walked with support until the age of 13 years and became wheelchair dependent. All patients classified as severe (patients 5â11) showed a severe motor impairment and did not achieve walking. These patients also suffered from poor to no head control.</p>
        <p>EEGs were performed in eight out of 11 patients. In five patients, EEGs were diffusely slow; in one patient, paroxysmal features were observed, with a normal background activity, and in another, diffuse dysrhythmic changes (patient 2). In one patient, clinical seizures were observed but could not be confirmed on EEG. No EEGs were performed in the other three patients because they did not show clinical evidence of seizures.</p>
        <p>An MRI was performed in 10 out of 11 patients. In four patients, an MRS (patients 1, 9, 10, and 11) was included in the same investigation. Patients categorized as mild or atypical presented MRI/MRS not typical for classical Canavan's disease, in agreement with their clinical presentations.</p>
        <p>A summary of genotype and phenotypic presentation of disease for all patients is described in Table <xref rid="humu23181-tbl-0001" ref-type="table-wrap">1</xref>.</p>
        <table-wrap id="humu23181-tbl-0001" xml:lang="en" orientation="portrait" position="float">
          <label>Table 1</label>
          <caption>
            <p>Genotypic, Clinical, and Biochemical Data of Patients with Novel <italic>ASPA</italic> Mutations<xref ref-type="fn" rid="humu23181-tbl1-note-0001">*</xref>
</p>
          </caption>
          <table frame="hsides" rules="groups">
            <col align="left" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <col align="center" span="1"/>
            <thead>
              <tr style="border-bottom:solid 1px #000000">
                <th align="left" rowspan="1" colspan="1">Patient number</th>
                <th align="center" rowspan="1" colspan="1">1</th>
                <th align="center" rowspan="1" colspan="1">2</th>
                <th align="center" rowspan="1" colspan="1">3</th>
                <th align="center" rowspan="1" colspan="1">4</th>
                <th align="center" rowspan="1" colspan="1">5</th>
                <th align="center" rowspan="1" colspan="1">6</th>
                <th align="center" rowspan="1" colspan="1">7</th>
                <th align="center" rowspan="1" colspan="1">8<xref ref-type="fn" rid="humu23181-tbl1-note-0003">a</xref>
</th>
                <th align="center" rowspan="1" colspan="1">9<xref ref-type="fn" rid="humu23181-tbl1-note-0003">a</xref>
</th>
                <th align="center" rowspan="1" colspan="1">10</th>
                <th align="center" rowspan="1" colspan="1">11</th>
              </tr>
              <tr style="border-bottom:solid 1px #000000" valign="bottom">
                <th align="left" valign="bottom" rowspan="1" colspan="1">Genotype<xref ref-type="fn" rid="humu23181-tbl1-note-0004">b</xref>
</th>
                <th align="center" valign="bottom" rowspan="1" colspan="1">
<bold>c.509T&gt;C, p.Ile170Thr</bold> c.914C&gt;A, p.Ala305Glu</th>
                <th align="center" valign="bottom" rowspan="1" colspan="1">
<bold>c.302G&gt;T, p.Gly101val</bold> c.432G&gt;A, p.(?)</th>
                <th align="center" valign="bottom" rowspan="1" colspan="1">
<bold>c.509T&gt;C, p.Ile170Thr</bold>
</th>
                <th align="center" valign="bottom" rowspan="1" colspan="1">
<bold>c.610G&gt;C, p.Asp204His</bold>
</th>
                <th align="center" valign="bottom" rowspan="1" colspan="1">
<bold>c.743A&gt;G, p.Gln248Arg</bold>
</th>
                <th align="center" valign="bottom" rowspan="1" colspan="1">
<bold>c.89T&gt;C, p.Leu30Pro</bold>
</th>
                <th align="center" valign="bottom" rowspan="1" colspan="1">
<bold>c.170C&gt;T, p.Ala57Val</bold> c.914C&gt;A, p.Ala305Glu</th>
                <th align="center" valign="bottom" rowspan="1" colspan="1">
<bold>c.70G&gt;A, p.Glu24Lys</bold>
</th>
                <th align="center" valign="bottom" rowspan="1" colspan="1">
<bold>c.70G&gt;A, p.Glu24Lys</bold>
</th>
                <th align="center" valign="bottom" rowspan="1" colspan="1">
<bold>c.385G&gt;A, p.Glu129Lys</bold> c.503G&gt;A, p.Arg168His</th>
                <th align="center" valign="bottom" rowspan="1" colspan="1">
<bold>c.539G&gt;T, p.Gly180Val</bold> c.556G&gt;T, p.Val186Phe</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td align="left" rowspan="1" colspan="1">Presentation (months)</td>
                <td align="center" rowspan="1" colspan="1">48</td>
                <td align="center" rowspan="1" colspan="1">54<xref ref-type="fn" rid="humu23181-tbl1-note-0005">c</xref>
</td>
                <td align="center" rowspan="1" colspan="1">19</td>
                <td align="center" rowspan="1" colspan="1">3</td>
                <td align="center" rowspan="1" colspan="1">4</td>
                <td align="center" rowspan="1" colspan="1">5</td>
                <td align="center" rowspan="1" colspan="1">1</td>
                <td align="center" rowspan="1" colspan="1">6</td>
                <td align="center" rowspan="1" colspan="1">3</td>
                <td align="center" rowspan="1" colspan="1">2</td>
                <td align="center" rowspan="1" colspan="1">6</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Macrocephaly</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Epilepsy</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">â</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Mental delay</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+<xref ref-type="fn" rid="humu23181-tbl1-note-0006">d</xref>
</td>
                <td align="center" rowspan="1" colspan="1">++<xref ref-type="fn" rid="humu23181-tbl1-note-0007">e</xref>
</td>
                <td align="center" rowspan="1" colspan="1">+++</td>
                <td align="center" rowspan="1" colspan="1">+++</td>
                <td align="center" rowspan="1" colspan="1">+++</td>
                <td align="center" rowspan="1" colspan="1">+++</td>
                <td align="center" rowspan="1" colspan="1">+++</td>
                <td align="center" rowspan="1" colspan="1">+++</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+++</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">No speech</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">?<xref ref-type="fn" rid="humu23181-tbl1-note-0008">f</xref>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Maximum speech</td>
                <td align="center" rowspan="1" colspan="1">Normal language</td>
                <td align="center" rowspan="1" colspan="1">Normal language</td>
                <td align="center" rowspan="1" colspan="1">Words</td>
                <td align="center" rowspan="1" colspan="1">Short sentences</td>
                <td align="center" rowspan="1" colspan="1">Sounds</td>
                <td align="center" rowspan="1" colspan="1">Sounds</td>
                <td align="center" rowspan="1" colspan="1">Sounds</td>
                <td align="center" rowspan="1" colspan="1">Sounds</td>
                <td align="center" rowspan="1" colspan="1">Sounds</td>
                <td align="center" rowspan="1" colspan="1">No</td>
                <td align="center" rowspan="1" colspan="1">?<xref ref-type="fn" rid="humu23181-tbl1-note-0008">f</xref>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Motor delay</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+++</td>
                <td align="center" rowspan="1" colspan="1">+++</td>
                <td align="center" rowspan="1" colspan="1">+++</td>
                <td align="center" rowspan="1" colspan="1">+++</td>
                <td align="center" rowspan="1" colspan="1">+++</td>
                <td align="center" rowspan="1" colspan="1">+++</td>
                <td align="center" rowspan="1" colspan="1">++</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Poor head control</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">No walking achieved</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">?<xref ref-type="fn" rid="humu23181-tbl1-note-0008">f</xref>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Increased NAA excretion (urine)</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">â</td>
                <td align="center" rowspan="1" colspan="1">+</td>
                <td align="center" rowspan="1" colspan="1">+</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Follow up duration (months)</td>
                <td align="center" rowspan="1" colspan="1">134</td>
                <td align="center" rowspan="1" colspan="1">432<xref ref-type="fn" rid="humu23181-tbl1-note-0009">g</xref>
</td>
                <td align="center" rowspan="1" colspan="1">120</td>
                <td align="center" rowspan="1" colspan="1">372</td>
                <td align="center" rowspan="1" colspan="1">109</td>
                <td align="center" rowspan="1" colspan="1">24<xref ref-type="fn" rid="humu23181-tbl1-note-0009">g</xref>
</td>
                <td align="center" rowspan="1" colspan="1">264<xref ref-type="fn" rid="humu23181-tbl1-note-0009">g</xref>
</td>
                <td align="center" rowspan="1" colspan="1">15</td>
                <td align="center" rowspan="1" colspan="1">92</td>
                <td align="center" rowspan="1" colspan="1">120</td>
                <td align="center" rowspan="1" colspan="1">6<xref ref-type="fn" rid="humu23181-tbl1-note-0009">g</xref>
</td>
              </tr>
              <tr>
                <td align="left" rowspan="1" colspan="1">Enzyme activity (% of WT) in HEK293 transfectants<xref ref-type="fn" rid="humu23181-tbl1-note-0010">h</xref>
</td>
                <td align="center" rowspan="1" colspan="1">5.5Â Â±Â 2.8</td>
                <td align="center" rowspan="1" colspan="1">&lt;1%</td>
                <td align="center" rowspan="1" colspan="1">5.5Â Â±Â 2.8</td>
                <td align="center" rowspan="1" colspan="1">12.4Â Â±Â 2.8</td>
                <td align="center" rowspan="1" colspan="1">&lt;1%</td>
                <td align="center" rowspan="1" colspan="1">&lt;1%</td>
                <td align="center" rowspan="1" colspan="1">&lt;1%</td>
                <td align="center" rowspan="1" colspan="1">&lt;1%</td>
                <td align="center" rowspan="1" colspan="1">&lt;1%</td>
                <td align="center" rowspan="1" colspan="1">&lt;1%</td>
                <td align="center" rowspan="1" colspan="1">&lt;1%</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="humu23181-tbl1-note-0001">
              <p>
<sup>*</sup>
</p>
              <p>of whom we received questionnaires. Clinical data from homozygous patients 12 (<bold>c.188G&gt;C, p.Arg63Thr</bold>), 13 (<bold>c.206T&gt;G, p.Leu69Arg</bold>), and 14 (<bold>c.857C&gt;A, p.Ala286Asp</bold>) are not available.</p>
            </fn>
            <fn id="humu23181-tbl1-note-0002">
              <p>
<italic>Notes</italic>: A + indicates the presence and a â indicates the absence of the phenotype. For mental and motor delay + means mild, ++ is moderate, and +++ means severe.</p>
            </fn>
            <fn id="humu23181-tbl1-note-0003">
              <label>a</label>
              <p>Patients are siblings.</p>
            </fn>
            <fn id="humu23181-tbl1-note-0004">
              <label>b</label>
              <p>One variant is shown for homozygous patients. Novel variants are highlighted in bold.</p>
            </fn>
            <fn id="humu23181-tbl1-note-0005">
              <label>c</label>
              <p>Infancy.</p>
            </fn>
            <fn id="humu23181-tbl1-note-0006">
              <label>d</label>
              <p>Attended normal school with support.</p>
            </fn>
            <fn id="humu23181-tbl1-note-0007">
              <label>e</label>
              <p>Autism.</p>
            </fn>
            <fn id="humu23181-tbl1-note-0008">
              <label>f</label>
              <p>Did not achieve normal milestone age.</p>
            </fn>
            <fn id="humu23181-tbl1-note-0009">
              <label>g</label>
              <p>Lost to follow up at.</p>
            </fn>
            <fn id="humu23181-tbl1-note-0010">
              <label>h</label>
              <p>For heterozygous patients, the activity indicated corresponds to the variant in bold.</p>
            </fn>
          </table-wrap-foot>
          <permissions>
            <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
          </permissions>
        </table-wrap>
      </sec>
      <sec id="humu23181-sec-0120">
        <title>Functional Analysis of Novel ASPA Variants</title>
        <p>Enzyme activity was determined in cell lysates of HEK293 transfected with the constructs described. Cell lysates transfected with WT <italic>ASPA</italic> displayed an activity of 6,180Â Â±Â 1,223Â nmol Asp/h/mg. This activity was 200âfold higher than the mock transfected lysates. Activities are expressed as % of WT activity. The majority of the studied variants presented with enzyme activities lower than 1% of the WT. The common variant p.Glu285Ala presented an activity of 2.7Â Â±Â 0.7% of the WT activity. The variant p.Ile170Thr presented 5.5Â Â±Â 2.8% of residual activity. The variant with the highest activity detected (12.4Â Â±Â 2.8%) was p.Asp204His.</p>
      </sec>
      <sec id="humu23181-sec-0130">
        <title>Western Blot</title>
        <p>Since most of the variants studied presented with very low enzyme activities, a Western Blot was performed to verify whether all variant proteins were expressed. All variants presented detectable expression of ASPA with no major differences concerning level of expression when compared to the WT (Fig. <xref rid="humu23181-fig-0003" ref-type="fig">3</xref>).</p>
        <fig fig-type="Figure" xml:lang="en" id="humu23181-fig-0003" orientation="portrait" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Expression levels of ASPA proteins in fusion with mGFP transiently transfected into Human Embryonic Kidney cells (HEK293) monitored by Western blot analysis after SDSâPAGE. Thirty micrograms of total protein was loaded per lane. An antibody against mGFP was used as primary antibody. The arrow points to the ASPAâmGFP fusion protein. The <sup>*</sup> indicates free mGFP.</p>
          </caption>
          <graphic id="nlm-graphic-7" xlink:href="HUMU-38-524-g003"/>
        </fig>
      </sec>
      <sec id="humu23181-sec-0140">
        <title>Structural Analysis</title>
        <p>Structural models for the 12 novel variants studied were generated (using the prediction tool SDM as described in section <italic>Materials and Methods</italic>) and compared with the WT structure. Overall the amino acid replacements did not cause major structural changes. This was also observed when Wijayasinghe etÂ al. (<xref rid="humu23181-bib-0037" ref-type="ref">2014</xref>) crystalized four ASPA variants. Regarding variant p.Glu24Lys, amino acid residue Glu24 is one of the Zn binding residues. Replacement of the residue Glu by Lys will change the local polarity of the residue and probably interfere with the bond stability of the cofactor, which could explain the decrease in enzyme activity. In addition, variant p.Glu24Ala resulted in complete ablation of enzyme activity [Le Coq etÂ al., <xref rid="humu23181-bib-0012" ref-type="ref">2008</xref>]. Replacement by Asp leads to decreased levels of bound Zn and no enzyme activity [Le Coq etÂ al., <xref rid="humu23181-bib-0012" ref-type="ref">2008</xref>]. The variant p.Glu24Gly has been reported in heterozygous state in one patient (the other allele harboring c.514C&gt;A, p.Pro181Thr) with classical CD [Zeng etÂ al., <xref rid="humu23181-bib-0041" ref-type="ref">2002</xref>].</p>
        <p>Regarding variant p.Leu30Pro, the amino acid Leu presents the highest propensity to form Î±âhelix structures and provide helix stability. Indeed, Leu30 is located in Î±âhelix 1. On the contrary, Pro cannot form Î±âhelices. It can only be incorporated in the first turn of the helix due to the ring structure, which is a helix breaker. This amino acid replacement is likely to cause a structural change in ASPA, which can explain the absence of enzyme activity. It was shown before that replacement of Leu by Pro leads to unfolding of helical regions [O'Neil and DeGrado, <xref rid="humu23181-bib-0020" ref-type="ref">1990</xref>; Strehlow etÂ al., <xref rid="humu23181-bib-0027" ref-type="ref">1991</xref>].</p>
        <p>The variant residue of p.Ala57Val, Ala57 is located on the first turn of Î±âhelix 2. Replacement by Val will not dramatically change the properties of the residue. However, Val residues are most often found in Î²âsheet structures and replacement of Ala by Val results most likely in structural changes that can explain the absence of enzyme activity observed for the p.Ala57Val variant.</p>
        <p>Regarding variant p.Arg63Thr, amino acid residue Arg63 is part of the catalytic center of ASPA and is important for stabilization of the substrate, meaning that replacement of that residue will likely result in an inactive enzyme, as observed.</p>
        <p>In the variant p.Leu69Arg, replacement of the branched nonâpolar amino acid residue Leu by the polar amino acid Arg with a longer side chain will likely have impact on the overall structure of the protein and result in a decreased enzyme activity.</p>
        <p>The affected residue in variant p.Gly101Val, Gly101 is very conserved in eukaryotes. Val is an amino acid residue with a larger side chain, which can result in a steric hindrance. In our system, this variant presented with no enzyme activity.</p>
        <p>Concerning the variant p.Glu129Lys, residue Glu129 contributes to intraâmonomer stability by establishing hydrogen bonds with Thr166. Replacement by Lys will hinder the formation of these stabilizing bonds, which can explain the observed inactivation.</p>
        <p>The variant p.Ile170Thr affects residue Ile 170, which is part of Î±âhelix 7. The in silico model predicts that the replacement of Ile170 by Thr results in disruption of the Î±âhelix. Although this replacement results in a decrease in enzyme activity (about 6% of WT), it is important to consider that among the studied variants this one presented with the second highest residual enzyme activity.</p>
        <p>About variant p.Gly180Val, replacement by Val will likely have an impact on protein structure due to the addition of the side chain.</p>
        <p>Variant p.Asp204His affects the very conserved (eukaryotes) Asp204. This residue is located at the surface of the protein. This variant was used for in silico secondary structure prediction and reported to cause conformational changes in the protein [Shinar etÂ al., <xref rid="humu23181-bib-0025" ref-type="ref">2004</xref>].</p>
        <p>Regarding variant p.Gln248Arg, Gln 248 is located in the dimer interface. Arg presents completely different properties, changing the size and polarity of the side chain of this residue. This replacement may affect the formation of the dimer, which can explain the inactivation of ASPA.</p>
        <p>The variant p.Ala286Asp affects a highly conserved amino acid residue in eukaryotes. Ala presents with a small non polar side chain. Replacement by Asp results in a dramatic increase in the size of the side chain. This could explain the nonâdetectable enzyme activity.</p>
      </sec>
    </sec>
    <sec id="humu23181-sec-0150">
      <title>Discussion</title>
      <p>Diagnosis of inborn errors of metabolism (IEM) has come a long way. For highly incapacitating diseases, like CD, with no available therapy the option of prenatal diagnosis is often very important for families with affected individuals. To prevent false positive or negative results, it is of utmost importance that the method used to diagnose the disorder is both accurate and specific. For CD, historically prenatal diagnosis was based on enzyme determinations in amniocytes. The extremely low ASPA activity in these cells represents an analytical challenge and unfortunately led to misdiagnosed cases in the past [Matalon etÂ al., <xref rid="humu23181-bib-0015" ref-type="ref">1992</xref>]. The introduction of stable isotope dilution analysis of amniotic fluid in our laboratory in 1991 [Jakobs etÂ al., <xref rid="humu23181-bib-0007" ref-type="ref">1991</xref>] offered a more reliable technique for this purpose. Later DNA analysis replaced these methods for the majority of prenatal diagnoses. Nowadays, nextâgeneration sequencing is becoming more and more a first step in the diagnosis of patients with disorders of unknown etiology including so far undetected IEM. This results in the identification of novel variants and mild or atypical phenotypic presentations. Therefore, a functional test is necessary to understand the significance of novel missense variants. We developed an overexpression system to characterize missense variants in the <italic>ASPA</italic> gene. This system bypasses the need for additional material from patients and can also be used to confirm pathogenicity of variants identified in familial cases.</p>
      <p>More than 100 mutations have been described in the <italic>ASPA</italic> gene. We developed a public database for these variants and included all published and novel variants (<ext-link ext-link-type="uri" xlink:href="http://www.lovd.nl/ASPA">http://www.lovd.nl/ASPA</ext-link>). We analyzed the effects of 12 novel <italic>ASPA</italic> missense mutations (detected in a total of 14 patients) as well as two common missense mutations (p.Glu285Ala and p.Ala305Glu). The 14 variants were transiently transfected into HEK293 cells, which are considered the most suitable system to study ASPA variants because it ensures the availability of all necessary codons [Wang and Viola, <xref rid="humu23181-bib-0036" ref-type="ref">2014</xref>].</p>
      <p>The activity measured for the WT (6,180Â Â±Â 1,223Â nmol Asp/hr/mg) and for the variant p.Glu285Ala (about 2% of WT) match the activities described in the literature [Kaul etÂ al., <xref rid="humu23181-bib-0009" ref-type="ref">1994</xref>; Moore etÂ al., <xref rid="humu23181-bib-0018" ref-type="ref">2003</xref>; Sommer and Sass, <xref rid="humu23181-bib-0026" ref-type="ref">2012</xref>], validating our method.</p>
      <p>Different phenotypic presentations have been described for CD. The classical severe form is the most common, but milder CD presentations have also been reported [Toft etÂ al., <xref rid="humu23181-bib-0031" ref-type="ref">1993</xref>; Shaag etÂ al., <xref rid="humu23181-bib-0024" ref-type="ref">1995</xref>; Zafeiriou etÂ al., <xref rid="humu23181-bib-0039" ref-type="ref">1999</xref>; Tacke etÂ al., <xref rid="humu23181-bib-0030" ref-type="ref">2005</xref>; Yalcinkaya etÂ al., <xref rid="humu23181-bib-0038" ref-type="ref">2005</xref>; Janson etÂ al., <xref rid="humu23181-bib-0008" ref-type="ref">2006</xref>; Velinov etÂ al., <xref rid="humu23181-bib-0035" ref-type="ref">2008</xref>; Delaney etÂ al., <xref rid="humu23181-bib-0005" ref-type="ref">2015</xref>; Nguyen and Ishak, <xref rid="humu23181-bib-0019" ref-type="ref">2015</xref>; Sarret etÂ al., <xref rid="humu23181-bib-0022" ref-type="ref">2016</xref>]. In our study, four patients showed an atypical or mild presentation (patients 1â4), whereas the remaining seven presented with the classical CD phenotype. In our study, we observed a correlation between the mutations detected in the mild cases and the variants with the relatively higher enzyme activities (p.Ile170Thr, p.Asp204His).</p>
      <p>Based on the functional studies, the biochemistry and the clinical information, we classify the following 10 variants as pathogenic mutations: p.Glu24Lys, p.Leu30Pro, p.Ala57Val, p.Arg63Thr, p.Leu69Arg, p.Gly101Val, p.Glu129Lys, p.Gly180Val, p.Gln248Arg, and p.Ala286Asp. All these variants were identified in patients with a severe phenotypic presentation of CD and showed less than 1% of WT ASPA residual activity in our system. The homozygous p.Asp204His mutation was detected in a 31âyearâold patient (patient 4). This variant showed a relatively high residual ASPA activity (12%) in our functional assay. The clinical features did fit with mild CD (macrocephaly, MRI characteristic for CD) and also largely increased NAA levels in urine were detected. We believe that variant p.Asp204His is responsible for milder CD presentation and therefore we also classify this variant as pathogenic. The variant p.Ile170Thr is more difficult to classify. The p.Ile170Thr was found in two patients with only a very mild increase of NAA in urine without further hallmark signs of CD. The two patients harboring this variant are currently 10 (patient 3) and 11 years old (patient 1). Because in the two other mild patients (patient 2 and 4), the clinical presentation became more severe with age (around 30 (patient 2) and 14 (patient 4)), the clinical phenotype may change with time. For the time being, we propose to consider this as a rare variant of unknown clinical significance. Identification of more patients and the additional data from disease progression of these two cases will help to assess the clinical significance of this variant. The mild presentation observed for patient 2 could potentially be explained by variant c.432G&gt;A. This variant was described before [Schober etÂ al., <xref rid="humu23181-bib-0023" ref-type="ref">2011</xref>]. Nucleotide c.432 is the last base (3â²end) of exon 2 and it will most likely affect the splice donor of intron 2, probably resulting in skipping of exon 2 and possibly allowing a small percentage of correctly transcribed <italic>ASPA</italic> mRNAs. The mild phenotype observed in this patient could be explained by the correct WT splicing of a small amount of <italic>ASPA</italic> mRNA product as described for other splice mutations [van Berge etÂ al., <xref rid="humu23181-bib-0033" ref-type="ref">2012</xref>] but mRNA studies are necessary to confirm this hypothesis.</p>
      <p>We report a correlation between <italic>ASPA</italic> mutation, enzyme activity and clinical presentation of CD. Such a correlation was observed before for CD [Zano etÂ al., <xref rid="humu23181-bib-0040" ref-type="ref">2013</xref>]. We describe 14 new patients with a total of 12 novel missense variants not characterized before. By the use of our functional assay, we have confirmed for 11 out of 12 that the variants are pathogenic. Three of the patients that presented with milder phenotype harbored the mutations that presented with the highest residual activities in our assay. It is remarkable that a residual activity of about 10% of WT can already be associated with a milder form of CD. This observation suggests that a slight increase in activity can already have a big impact on the quality of life of patients and families that have to deal with CD. This newly developed functional assay is implemented in our diagnostic facility and will improve not only diagnostics for new cases, but it can also be helpful to identify potential therapies.</p>
    </sec>
    <sec id="humu23181-sec-0170">
      <p>
<italic>Disclosure statement</italic>: The authors declare no conflict of interests.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supporting information</title>
      <supplementary-material content-type="local-data">
        <caption>
          <p>Table S1. Oligonucleotides used for cloning and site directed mutagenesis reactions</p>
        </caption>
        <media xlink:href="HUMU-38-524-s001.pdf">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="humu23181-sec-0160">
      <title>Acknowledgments</title>
      <p>The authors acknowledge all biochemists involved in the diagnosis of this patient cohort. We thank Prof C. Jakobs who initiated the investigations for the improvements of the diagnosis of CD already in the nineties at the Metabolic Unit, VU University Medical Center Amsterdam, The Netherlands.</p>
    </ack>
    <ref-list id="humu23181-bibl-0001">
      <title>References</title>
      <ref id="humu23181-bib-0001">
        <mixed-citation publication-type="journal" id="humu23181-cit-0001">
<string-name>
<surname>Baslow</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Suckow</surname>
<given-names>RF</given-names>
</string-name>, <string-name>
<surname>Sapirstein</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Hungund</surname>
<given-names>BL</given-names>
</string-name>. <year>1999</year>
<article-title>Expression of aspartoacylase activity in cultured rat macroglial cells is limited to oligodendrocytes</article-title>. <source>J Mol Neurosci</source>
<volume>13</volume>:<fpage>47</fpage>â<lpage>53</lpage>.<pub-id pub-id-type="pmid">10691291</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0002">
        <mixed-citation publication-type="journal" id="humu23181-cit-0002">
<string-name>
<surname>Betsalel</surname>
<given-names>OT</given-names>
</string-name>, <string-name>
<surname>Pop</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Rosenberg</surname>
<given-names>EH</given-names>
</string-name>, <string-name>
<surname>FernandezâOjeda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jakobs</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Salomons</surname>
<given-names>GS</given-names>
</string-name>. <year>2012</year>
<article-title>Detection of variants in SLC6A8 and functional analysis of unclassified missense variants</article-title>. <source>Mol Genet Metab</source>
<volume>105</volume>:<fpage>596</fpage>â<lpage>601</lpage>.<pub-id pub-id-type="pmid">22281021</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0003">
        <mixed-citation publication-type="journal" id="humu23181-cit-0003">
<string-name>
<surname>Bitto</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Bingman</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Wesenberg</surname>
<given-names>GE</given-names>
</string-name>, <string-name>
<surname>McCoy</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Phillips</surname>
<given-names>GN</given-names>, <suffix>Jr</suffix>
</string-name>. <year>2007</year>
<article-title>Structure of aspartoacylase, the brain enzyme impaired in Canavan disease</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>104</volume>:<fpage>456</fpage>â<lpage>461</lpage>.<pub-id pub-id-type="pmid">17194761</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0004">
        <mixed-citation publication-type="journal" id="humu23181-cit-0004">
<string-name>
<surname>Canavan</surname>
<given-names>MM</given-names>
</string-name>. <year>1931</year>
<article-title>Schilder's encephalitis perioxalisdiffusa</article-title>. <source>Neurol</source>
<fpage>299</fpage>â<lpage>308</lpage>.</mixed-citation>
      </ref>
      <ref id="humu23181-bib-0005">
        <mixed-citation publication-type="journal" id="humu23181-cit-0005">
<string-name>
<surname>Delaney</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>Kralik</surname>
<given-names>SF</given-names>
</string-name>, <string-name>
<surname>Hainline</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>Golomb</surname>
<given-names>MR</given-names>
</string-name>. <year>2015</year>
<article-title>An atypical case of Canavan disease with strokeâlike presentation</article-title>. <source>Pediatr Neurol</source>
<volume>52</volume>:<fpage>218</fpage>â<lpage>221</lpage>.<pub-id pub-id-type="pmid">25497124</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0006">
        <mixed-citation publication-type="journal" id="humu23181-cit-0006">
<string-name>
<surname>Feigenbaum</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Moore</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Clarke</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hewson</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chitayat</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ray</surname>
<given-names>PN</given-names>
</string-name>, <string-name>
<surname>Stockley</surname>
<given-names>TL</given-names>
</string-name>. <year>2004</year>
<article-title>Canavan disease: Carrierâfrequency determination in the Ashkenazi Jewish population and development of a novel molecular diagnostic assay</article-title>. <source>Am J Med Genet A</source>
<volume>124A</volume>:<fpage>142</fpage>â<lpage>147</lpage>.<pub-id pub-id-type="pmid">14699612</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0007">
        <mixed-citation publication-type="journal" id="humu23181-cit-0007">
<string-name>
<surname>Jakobs</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>ten Brink</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Langelaar</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Zee</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Stellaard</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Macek</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Srsnova</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Srsen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kleijer</surname>
<given-names>WJ</given-names>
</string-name>. <year>1991</year>
<article-title>Stable isotope dilution analysis of Nâacetylaspartic acid in CSF, blood, urine and amniotic fluid: Accurate postnatal diagnosis and the potential for prenatal diagnosis of Canavan disease</article-title>. <source>J Inherit Metab Dis</source>
<volume>14</volume>:<fpage>653</fpage>â<lpage>660</lpage>.<pub-id pub-id-type="pmid">1779610</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0008">
        <mixed-citation publication-type="journal" id="humu23181-cit-0008">
<string-name>
<surname>Janson</surname>
<given-names>CG</given-names>
</string-name>, <string-name>
<surname>Kolodny</surname>
<given-names>EH</given-names>
</string-name>, <string-name>
<surname>Zeng</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Raghavan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pastores</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Torres</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Assadi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>McPhee</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Goldfarb</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Saslow</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Freese</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Bilaniuk</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Shera</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Leone</surname>
<given-names>P</given-names>
</string-name>
<year>2006</year>
<article-title>Mildâonset presentation of Canavan's disease associated with novel G212A point mutation in aspartoacylase gene</article-title>. <source>Ann Neurol</source>
<volume>59</volume>:<fpage>428</fpage>â<lpage>431</lpage>.<pub-id pub-id-type="pmid">16437572</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0009">
        <mixed-citation publication-type="journal" id="humu23181-cit-0009">
<string-name>
<surname>Kaul</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>GP</given-names>
</string-name>, <string-name>
<surname>Aloya</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Balamurugan</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Petrosky</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Michals</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Matalon</surname>
<given-names>R</given-names>
</string-name>. <year>1994</year>
<article-title>Canavan disease: Mutations among Jewish and nonâJewish patients</article-title>. <source>Am J Hum Genet</source>
<volume>55</volume>:<fpage>34</fpage>â<lpage>41</lpage>.<pub-id pub-id-type="pmid">8023850</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0010">
        <mixed-citation publication-type="journal" id="humu23181-cit-0010">
<string-name>
<surname>Kronn</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Oddoux</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Phillips</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ostrer</surname>
<given-names>H</given-names>
</string-name>. <year>1995</year>
<article-title>Prevalence of Canavan disease heterozygotes in the New York metropolitan Ashkenazi Jewish population</article-title>. <source>Am J Hum Genet</source>
<volume>57</volume>:<fpage>1250</fpage>â<lpage>1252</lpage>.<pub-id pub-id-type="pmid">7485179</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0011">
        <mixed-citation publication-type="journal" id="humu23181-cit-0011">
<string-name>
<surname>Le Coq</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>An</surname>
<given-names>HJ</given-names>
</string-name>, <string-name>
<surname>Lebrilla</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Viola</surname>
<given-names>RE</given-names>
</string-name>. <year>2006</year>
<article-title>Characterization of human aspartoacylase: The brain enzyme responsible for Canavan disease</article-title>. <source>Biochemistry</source>
<volume>45</volume>:<fpage>5878</fpage>â<lpage>5884</lpage>.<pub-id pub-id-type="pmid">16669630</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0012">
        <mixed-citation publication-type="journal" id="humu23181-cit-0012">
<string-name>
<surname>Le Coq</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Pavlovsky</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Malik</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Sanishvili</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Viola</surname>
<given-names>RE</given-names>
</string-name>. <year>2008</year>
<article-title>Examination of the mechanism of human brain aspartoacylase through the binding of an intermediate analogue</article-title>. <source>Biochemistry</source>
<volume>47</volume>:<fpage>3484</fpage>â<lpage>3492</lpage>.<pub-id pub-id-type="pmid">18293939</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0013">
        <mixed-citation publication-type="journal" id="humu23181-cit-0013">
<string-name>
<surname>Leone</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Shera</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>McPhee</surname>
<given-names>SW</given-names>
</string-name>, <string-name>
<surname>Francis</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Kolodny</surname>
<given-names>EH</given-names>
</string-name>, <string-name>
<surname>Bilaniuk</surname>
<given-names>LT</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Assadi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Goldfarb</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Goldman</surname>
<given-names>HW</given-names>
</string-name>, <string-name>Freese A</string-name>, <string-name>Young D</string-name>, <string-name>During M</string-name>, <string-name>Samulki RJ</string-name>, <string-name>Janson CG</string-name>
<year>2012</year>
<article-title>Longâterm followâup after gene therapy for canavan disease</article-title>. <source>Sci Transl Med</source>
<volume>4</volume>:<fpage>165ra163</fpage>.</mixed-citation>
      </ref>
      <ref id="humu23181-bib-0014">
        <mixed-citation publication-type="journal" id="humu23181-cit-0014">
<string-name>
<surname>Matalon</surname>
<given-names>R</given-names>
</string-name>. <year>1997</year>
<article-title>Canavan disease: Diagnosis and molecular analysis</article-title>. <source>Genet Test</source>
<volume>1</volume>:<fpage>21</fpage>â<lpage>25</lpage>.<pub-id pub-id-type="pmid">10464621</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0015">
        <mixed-citation publication-type="journal" id="humu23181-cit-0015">
<string-name>
<surname>Matalon</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Michals</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Gashkoff</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kaul</surname>
<given-names>R</given-names>
</string-name>. <year>1992</year>
<article-title>Prenatal diagnosis of Canavan disease</article-title>. <source>J Inherit Metab Dis</source>
<volume>15</volume>:<fpage>392</fpage>â<lpage>394</lpage>.<pub-id pub-id-type="pmid">1405477</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0016">
        <mixed-citation publication-type="journal" id="humu23181-cit-0016">
<string-name>
<surname>Matalon</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Michals</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kaul</surname>
<given-names>R</given-names>
</string-name>. <year>1995</year>
<article-title>Canavan disease: From spongy degeneration to molecular analysis</article-title>. <source>J Pediatr</source>
<volume>127</volume>:<fpage>511</fpage>â<lpage>517</lpage>.<pub-id pub-id-type="pmid">7562269</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0017">
        <mixed-citation publication-type="journal" id="humu23181-cit-0017">
<string-name>
<surname>Matalon</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Michals</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sebesta</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Deanching</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gashkoff</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Casanova</surname>
<given-names>J</given-names>
</string-name>. <year>1988</year>
<article-title>Aspartoacylase deficiency and Nâacetylaspartic aciduria in patients with Canavan disease</article-title>. <source>Am J Med Genet</source>
<volume>29</volume>:<fpage>463</fpage>â<lpage>471</lpage>.<pub-id pub-id-type="pmid">3354621</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0018">
        <mixed-citation publication-type="journal" id="humu23181-cit-0018">
<string-name>
<surname>Moore</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Le</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Faehnle</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Viola</surname>
<given-names>RE</given-names>
</string-name>. <year>2003</year>
<article-title>Purification and preliminary characterization of brain aspartoacylase</article-title>. <source>Arch Biochem Biophys</source>
<volume>413</volume>:<fpage>1</fpage>â<lpage>8</lpage>.<pub-id pub-id-type="pmid">12706335</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0019">
        <mixed-citation publication-type="journal" id="humu23181-cit-0019">
<string-name>
<surname>Nguyen</surname>
<given-names>HV</given-names>
</string-name>, <string-name>
<surname>Ishak</surname>
<given-names>GE</given-names>
</string-name>. <year>2015</year>
<article-title>Canavan diseaseâUnusual imaging features in a child with mild clinical presentation</article-title>. <source>Pediatr Radiol</source>
<volume>45</volume>:<fpage>457</fpage>â<lpage>460</lpage>.<pub-id pub-id-type="pmid">25107638</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0020">
        <mixed-citation publication-type="journal" id="humu23181-cit-0020">
<string-name>
<surname>O'Neil</surname>
<given-names>KT</given-names>
</string-name>, <string-name>
<surname>DeGrado</surname>
<given-names>WF</given-names>
</string-name>. <year>1990</year>
<article-title>A thermodynamic scale for the helixâforming tendencies of the commonly occurring amino acids</article-title>. <source>Science</source>
<volume>250</volume>:<fpage>646</fpage>â<lpage>651</lpage>.<pub-id pub-id-type="pmid">2237415</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0021">
        <mixed-citation publication-type="journal" id="humu23181-cit-0021">
<string-name>
<surname>Pettersen</surname>
<given-names>EF</given-names>
</string-name>, <string-name>
<surname>Goddard</surname>
<given-names>TD</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Couch</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Greenblatt</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Meng</surname>
<given-names>EC</given-names>
</string-name>, <string-name>
<surname>Ferrin</surname>
<given-names>TE</given-names>
</string-name>. <year>2004</year>
<article-title>UCSF ChimeraâA visualization system for exploratory research and analysis</article-title>. <source>J Comput Chem</source>
<volume>25</volume>:<fpage>1605</fpage>â<lpage>1612</lpage>.<pub-id pub-id-type="pmid">15264254</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0022">
        <mixed-citation publication-type="journal" id="humu23181-cit-0022">
<string-name>
<surname>Sarret</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>BoespflugâTanguy</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Rodriguez</surname>
<given-names>D</given-names>
</string-name>. <year>2016</year>
<article-title>Atypical clinical and radiological course of a patient with Canavan disease</article-title>. <source>Metab Brain Dis</source>
<volume>31</volume>:<fpage>475</fpage>â<lpage>479</lpage>.<pub-id pub-id-type="pmid">26586007</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0023">
        <mixed-citation publication-type="journal" id="humu23181-cit-0023">
<string-name>
<surname>Schober</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Luetschg</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hoeliner</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Kalb</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Simma</surname>
<given-names>B</given-names>
</string-name>. <year>2011</year>
<article-title>Canavan disease: A novel mutation</article-title>. <source>Pediatr Neurol</source>
<volume>45</volume>:<fpage>256</fpage>â<lpage>258</lpage>.<pub-id pub-id-type="pmid">21907889</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0024">
        <mixed-citation publication-type="journal" id="humu23181-cit-0024">
<string-name>
<surname>Shaag</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Anikster</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Christensen</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Glustein</surname>
<given-names>JZ</given-names>
</string-name>, <string-name>
<surname>Fois</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Michelakakis</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nigro</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Pronicka</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Ribes</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Zabot</surname>
<given-names>MT</given-names>
</string-name>
<year>1995</year>
<article-title>The molecular basis of canavan (aspartoacylase deficiency) disease in European nonâJewish patients</article-title>. <source>Am J Hum Genet</source>
<volume>57</volume>:<fpage>572</fpage>â<lpage>580</lpage>.<pub-id pub-id-type="pmid">7668285</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0025">
        <mixed-citation publication-type="journal" id="humu23181-cit-0025">
<string-name>
<surname>Shinar</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>BenâZeev</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Anikster</surname>
<given-names>Y</given-names>
</string-name>. <year>2004</year>
<article-title>The secondary structure of aspartoacylase and its Canavan variants: A prediction</article-title>. <source>J Neurol</source>
<volume>251</volume>(<issue>Suppl 1</issue>):<fpage>95</fpage>.</mixed-citation>
      </ref>
      <ref id="humu23181-bib-0026">
        <mixed-citation publication-type="journal" id="humu23181-cit-0026">
<string-name>
<surname>Sommer</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sass</surname>
<given-names>JO</given-names>
</string-name>. <year>2012</year>
<article-title>Expression of aspartoacylase (ASPA) and Canavan disease</article-title>. <source>Gene</source>
<volume>505</volume>:<fpage>206</fpage>â<lpage>210</lpage>.<pub-id pub-id-type="pmid">22750302</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0027">
        <mixed-citation publication-type="journal" id="humu23181-cit-0027">
<string-name>
<surname>Strehlow</surname>
<given-names>KG</given-names>
</string-name>, <string-name>
<surname>Robertson</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Baldwin</surname>
<given-names>RL</given-names>
</string-name>. <year>1991</year>
<article-title>Proline for alanine substitutions in the Câpeptide helix of ribonuclease A</article-title>. <source>Biochemistry</source>
<volume>30</volume>:<fpage>5810</fpage>â<lpage>5814</lpage>.<pub-id pub-id-type="pmid">2043620</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0028">
        <mixed-citation publication-type="journal" id="humu23181-cit-0028">
<string-name>
<surname>Surendran</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bamforth</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tyring</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Goodman</surname>
<given-names>SI</given-names>
</string-name>, <string-name>
<surname>Matalon</surname>
<given-names>R</given-names>
</string-name>. <year>2003a</year>
<article-title>Mild elevation of Nâacetylaspartic acid and macrocephaly: Diagnostic problem</article-title>. <source>J Child Neurol</source>
<volume>18</volume>:<fpage>809</fpage>â<lpage>812</lpage>.<pub-id pub-id-type="pmid">14696913</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0029">
        <mixed-citation publication-type="journal" id="humu23181-cit-0029">
<string-name>
<surname>Surendran</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>MichalsâMatalon</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Quast</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Tyring</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ezell</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Matalon</surname>
<given-names>R</given-names>
</string-name>. <year>2003b</year>
<article-title>Canavan disease: A monogenic trait with complex genomic interaction</article-title>. <source>Mol Genet Metab</source>
<volume>80</volume>:<fpage>74</fpage>â<lpage>80</lpage>.<pub-id pub-id-type="pmid">14567959</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0030">
        <mixed-citation publication-type="journal" id="humu23181-cit-0030">
<string-name>
<surname>Tacke</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Olbrich</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Sass</surname>
<given-names>JO</given-names>
</string-name>, <string-name>
<surname>Fekete</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Horvath</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ziyeh</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kleijer</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Rolland</surname>
<given-names>MO</given-names>
</string-name>, <string-name>
<surname>Fisher</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Payne</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Vargiami</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Zafeirou</surname>
<given-names>DI</given-names>
</string-name>, <string-name>
<surname>Omran</surname>
<given-names>H</given-names>
</string-name>
<year>2005</year>
<article-title>Possible genotypeâphenotype correlations in children with mild clinical course of Canavan disease</article-title>. <source>Neuropediatrics</source>
<volume>36</volume>:<fpage>252</fpage>â<lpage>255</lpage>.<pub-id pub-id-type="pmid">16138249</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0031">
        <mixed-citation publication-type="journal" id="humu23181-cit-0031">
<string-name>
<surname>Toft</surname>
<given-names>PB</given-names>
</string-name>, <string-name>
<surname>GeissâHoltorff</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Rolland</surname>
<given-names>MO</given-names>
</string-name>, <string-name>
<surname>Pryds</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>MullerâForell</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Christensen</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Lehnert</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Lou</surname>
<given-names>HC</given-names>
</string-name>, <string-name>
<surname>Ott</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hennig</surname>
<given-names>J</given-names>
</string-name>
<year>1993</year>
<article-title>Magnetic resonance imaging in juvenile Canavan disease</article-title>. <source>Eur J Pediatr</source>
<volume>152</volume>:<fpage>750</fpage>â<lpage>753</lpage>.<pub-id pub-id-type="pmid">8223809</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0032">
        <mixed-citation publication-type="journal" id="humu23181-cit-0032">
<string-name>
<surname>Traeger</surname>
<given-names>EC</given-names>
</string-name>, <string-name>
<surname>Rapin</surname>
<given-names>I</given-names>
</string-name>. <year>1998</year>
<article-title>The clinical course of Canavan disease</article-title>. <source>Pediatr Neurol</source>
<volume>18</volume>:<fpage>207</fpage>â<lpage>212</lpage>.<pub-id pub-id-type="pmid">9568915</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0033">
        <mixed-citation publication-type="journal" id="humu23181-cit-0033">
<string-name>
<surname>van Berge</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Dooves</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>van Berkel</surname>
<given-names>CG</given-names>
</string-name>, <string-name>
<surname>Polder</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>van der Knaap</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Scheper</surname>
<given-names>GC</given-names>
</string-name>. <year>2012</year>
<article-title>Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation is associated with cellâtypeâdependent splicing of mtAspRS mRNA</article-title>. <source>Biochem J</source>
<volume>441</volume>:<fpage>955</fpage>â<lpage>962</lpage>.<pub-id pub-id-type="pmid">22023289</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0034">
        <mixed-citation publication-type="journal" id="humu23181-cit-0034">
<string-name>
<surname>van Bogaert</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Bertrand</surname>
<given-names>I</given-names>
</string-name>. <year>1949</year>
<article-title>Sur une idiotie familiale avec dÃ©gÃ©nÃ©rescence spongieuse du nÃ©vraxe (note preliminaire)</article-title>. <source>Acta Neurol</source>
<volume>49</volume>:<fpage>572</fpage>â<lpage>587</lpage>.</mixed-citation>
      </ref>
      <ref id="humu23181-bib-0035">
        <mixed-citation publication-type="journal" id="humu23181-cit-0035">
<string-name>
<surname>Velinov</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zellers</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Styles</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wisniewski</surname>
<given-names>K</given-names>
</string-name>. <year>2008</year>
<article-title>Homozygosity for mutation G212A of the gene for aspartoacylase is associated with atypical form of Canavan's disease</article-title>. <source>Clin Genet</source>
<volume>73</volume>:<fpage>288</fpage>â<lpage>289</lpage>.<pub-id pub-id-type="pmid">18070137</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0036">
        <mixed-citation publication-type="journal" id="humu23181-cit-0036">
<string-name>
<surname>Wang</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Viola</surname>
<given-names>RE</given-names>
</string-name>. <year>2014</year>
<article-title>Reexamination of aspartoacylase: Is this human enzyme really a glycoprotein?</article-title>
<source>Arch Biochem Biophys</source>
<volume>548</volume>:<fpage>66</fpage>â<lpage>73</lpage>.<pub-id pub-id-type="pmid">24632142</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0037">
        <mixed-citation publication-type="journal" id="humu23181-cit-0037">
<string-name>
<surname>Wijayasinghe</surname>
<given-names>YS</given-names>
</string-name>, <string-name>
<surname>Pavlovsky</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Viola</surname>
<given-names>RE</given-names>
</string-name>. <year>2014</year>
<article-title>Aspartoacylase catalytic deficiency as the cause of Canavan disease: A structural perspective</article-title>. <source>Biochemistry</source>
<volume>53</volume>:<fpage>4970</fpage>â<lpage>4978</lpage>.<pub-id pub-id-type="pmid">25003821</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0038">
        <mixed-citation publication-type="journal" id="humu23181-cit-0038">
<string-name>
<surname>Yalcinkaya</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Benbir</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Salomons</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Karaarslan</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Rolland</surname>
<given-names>MO</given-names>
</string-name>, <string-name>
<surname>Jakobs</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>van der Knaap</surname>
<given-names>MS</given-names>
</string-name>. <year>2005</year>
<article-title>Atypical MRI findings in Canavan disease: A patient with a mild course</article-title>. <source>Neuropediatrics</source>
<volume>36</volume>:<fpage>336</fpage>â<lpage>339</lpage>.<pub-id pub-id-type="pmid">16217711</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0039">
        <mixed-citation publication-type="journal" id="humu23181-cit-0039">
<string-name>
<surname>Zafeiriou</surname>
<given-names>DI</given-names>
</string-name>, <string-name>
<surname>Kleijer</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Maroupoulos</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Anastasiou</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>AugoustidouâSavvopoulou</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Papadopoulou</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Kontopoulos</surname>
<given-names>EE</given-names>
</string-name>, <string-name>
<surname>Fagan</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Payne</surname>
<given-names>S</given-names>
</string-name>. <year>1999</year>
<article-title>Protracted course of Nâacetylaspartic aciduria in two nonâJewish siblings: Identical clinical and magnetic resonance imaging findings</article-title>. <source>Brain Dev</source>
<volume>21</volume>:<fpage>205</fpage>â<lpage>208</lpage>.<pub-id pub-id-type="pmid">10372908</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0040">
        <mixed-citation publication-type="journal" id="humu23181-cit-0040">
<string-name>
<surname>Zano</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wijayasinghe</surname>
<given-names>YS</given-names>
</string-name>, <string-name>
<surname>Malik</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Viola</surname>
<given-names>RE</given-names>
</string-name>. <year>2013</year>
<article-title>Relationship between enzyme properties and disease progression in Canavan disease</article-title>. <source>J Inherit Metab Dis</source>
<volume>36</volume>:<fpage>1</fpage>â<lpage>6</lpage>.<pub-id pub-id-type="pmid">22850825</pub-id></mixed-citation>
      </ref>
      <ref id="humu23181-bib-0041">
        <mixed-citation publication-type="journal" id="humu23181-cit-0041">
<string-name>
<surname>Zeng</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>ZH</given-names>
</string-name>, <string-name>
<surname>Ribeiro</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Leone</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>De</surname>
<given-names>GR</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Raghavan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ong</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Pastores</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Kolodny</surname>
<given-names>EH</given-names>
</string-name>. <year>2002</year>
<article-title>Identification and characterization of novel mutations of the aspartoacylase gene in nonâJewish patients with Canavan disease</article-title>. <source>J Inherit Metab Dis</source>
<volume>25</volume>:<fpage>557</fpage>â<lpage>570</lpage>.<pub-id pub-id-type="pmid">12638939</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>